Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > REGULATORY
REGULATORY
- Planning to Resume “Public-Private Dialog” by Year-End: EAD Director Kamata
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize Korosho at Hearings
October 26, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 26, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
- US FDA Approves 1st Generic Versions of Zyprexa, Eli Lilly’s Top Mainstay Product
October 26, 2011
- Subcommittee to Recommend Use of Most-recent 3-year Averages in Drug Cost Calculation
October 26, 2011
- Chuikyo Subcommittee Approves Revision of Foreign Price Adjustment Rule
October 26, 2011
- Korosho to Take Stricter Look at Companies’ Market Size Forecasts
October 26, 2011
- JMA, JPA Oppose Increase in Patients’ Copayments for OTC-like Drugs
October 26, 2011
- TPP Could Have Major Impact on NHI Price System: Ms Weatherall of University of Queensland
October 26, 2011
- Patent Office to Revise Rules for Granting Patent Extensions
October 25, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 25, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 25, 2011
- EMA Confirms Usefulness of Pioglitazone-Containing Medicines as 2nd, 3rd Line Treatment Options: Takeda
October 24, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
- Korosho Receives 270 Requests for Development of Unapproved Drugs, Indications in 2nd Round
October 24, 2011
- Groups of Care Providers, Patients Against Creating Compensation System for Injury from Anticancer Drugs
October 22, 2011
- Drug Discovery Support Agency Will Not Compete with Private Sector: Mr Tsuchiya
October 21, 2011
- CSIMC Recommended Approval for Reimbursement on Piecework for 2 High-Priced Drugs
October 21, 2011
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…